Company: HCTI
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001213900-25-109581
Chunk: 22

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
 Agreement”) with institutional investors (the “Investors”)
for the private placement of 145,344 units (each a, “Unit”), each Unit consisting of one share of the Company’s common
stock (“Common Stock”) or one pre-funded warrant (a “Pre-Funded Warrant”) to purchase one share of common stock,
one Series A Warrant (a “Series A Warrant”) to purchase one share of common stock and one Series B Warrant (a “Series
B Warrant” and together with the Series A Warrant, the “Purchase Warrants”) to purchase one share of common stock at
an offering price of $104.58 per Unit (or $104.58 per Unit in the case of Units that include pre-funded warrants). The Common Stock, the
Pre-Funded Warrants and the Purchase Warrants included in the Units and the Common Stock underlying the Pre-Funded Warrants and the Purchase
Warrants are collectively referred to herein as the “Securities” and the Securities, other than the Pre-Funded Warrants, and
the Purchase Warrants shall be referred to herein as the “Registrable Securities.” The entire transaction has been priced
at the market under Nasdaq rules and closed on February 28, 2025. 

The initial exercise price for both the Series
A Warrants and Series B Warrants is $209.16 per share and both terminate on the fifth anniversary of the later of (x) effective date
of stockholder approval and (y) the earlier of (i) the effective date of the registration statement (the “Registration Statement”)
filed by the Company to register the Registerable Securities or (ii) the date that the Registerable Securities can be sold, assigned
or transferred without restriction or limitation pursuant to Rule 144 promulgated under the 1933 Act, as amended. The Purchase Warrants
may not be exercised until stockholder approval of the exercise of the Purchase Warrants is effective (“Stockholder Approval”).
The Company has agreed in the Purchase Agreement to obtain Stockholder Approval within 60 days of the closing date of the offering.

The
Company received gross proceeds of approximately $15,200. Net proceeds to the Company were approximately $13,676, after deducting placement
agent fees and other expenses payable by the Company, reflected
in the equity.

The Company allocated the proceeds between the
Common Stock, Pre-Funded Warrants, and Common Warrants (some of which were